CN113842411A - Traditional Chinese medicine composition of lucid ganoderma nerve-soothing capsule and preparation method thereof - Google Patents
Traditional Chinese medicine composition of lucid ganoderma nerve-soothing capsule and preparation method thereof Download PDFInfo
- Publication number
- CN113842411A CN113842411A CN202111271142.8A CN202111271142A CN113842411A CN 113842411 A CN113842411 A CN 113842411A CN 202111271142 A CN202111271142 A CN 202111271142A CN 113842411 A CN113842411 A CN 113842411A
- Authority
- CN
- China
- Prior art keywords
- group
- nerve
- traditional chinese
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition of a ganoderma lucidum nerve-soothing capsule and a preparation method thereof, the traditional Chinese medicine composition is prepared by eight raw material medicines of ganoderma lucidum, cortex albiziae, caulis polygoni multiflori, schisandra chinensis, glossy privet fruit, Chinese date, spina date seed and liquorice, and the ganoderma lucidum is crushed into coarse powder for standby; extracting caulis Polygoni Multiflori and fructus Schisandrae chinensis with ethanol to obtain fluid extract; extracting the rest cortex Albizziae, fructus Ligustri Lucidi, fructus Jujubae, semen Ziziphi Spinosae, and Glycyrrhrizae radix with water to obtain fluid extract; mixing the coarse powder with the ethanol extract and water extract, drying, pulverizing, granulating, grading, and making into capsule. The invention has better curative effect, reasonable compatibility, clear effect, safety, no toxic or side effect, high safety after long-term administration and no dependence. The invention has the effects of nourishing blood and soothing nerves. Can be used for treating insomnia, dreaminess, dizziness, asthenia, and neurasthenia.
Description
Technical Field
The invention relates to a traditional Chinese medicine composition of a ganoderma lucidum nerve-soothing capsule and a preparation method thereof, belonging to the technical field of pharmacy.
Background
Neurasthenia is characterized by psychostimulant and fatigable symptoms, and is mainly manifested by emotional irritability, vexation, and tension, and physiological dysfunction symptoms such as muscular tension pain and sleep disorder. The etiology and pathogenesis of neurasthenia are not yet determined. It is generally thought that, on the basis of the predisposition of an individual, when the individual is subjected to a greater psychological stress and fails to respond to a pair, the energy regulation mechanism of his mental activities is affected, thus producing a neurasthenia symptom. In recent years, people suffering from neurasthenia tend to be younger, and people who study or work at high intensity for a long time and have high pressure and insomnia for a long time are easy to suffer from neurasthenia. Seriously affecting the health of people. Traditional Chinese medicine compositions for treating neurasthenia are numerous, but most of the traditional Chinese medicine compositions are not ideal in curative effect, and the prior art, disclosed in Chinese patent publications, is as follows: 1. chinese patent gazette 2010, 5 months and 5 days discloses a patent application with the name of 'a traditional Chinese medicine composition for neurasthenia, a preparation method and a quality control method thereof', and the publication number is CN101700270A, wherein the raw material medicines of the traditional Chinese medicine composition consist of two traditional Chinese medicinal materials of astragalus and lucid ganoderma, and are processed into capsules and tablets by the processes of extraction and the like; can be used for treating neurasthenia, insomnia, amnesia, anorexia, tiredness, short breath, hyperhidrosis, etc. 2. Chinese patent gazette 2014, 2 months and 5 days discloses a patent application with the name of ganoderma lucidum nerve-soothing composition, liniment and a preparation method and application thereof, wherein the patent application with the name of CN103550629A is published, raw material medicines of the traditional Chinese medicine composition comprise twelve traditional Chinese medicines of ganoderma lucidum, hericium erinaceus, radix puerariae, lotus plumule, emblic leafflower fruit, poria cocos, endothelium corneum gigeriae galli, malt, mulberry leaf, oyster, Chinese date and liquorice, and the liniment is prepared by processing the traditional Chinese medicines through processes of water extraction and the like and has the effects of strengthening spleen, helping digestion, clearing away the heart-fire and soothing the nerves. The inventor has made a lot of researches on the prior art, and found that the 2 kinds of traditional Chinese medicine compositions disclosed in the patent publications have no ideal curative effect on neurasthenia, so that the development of the traditional Chinese medicine composition for treating neurasthenia, which takes Chinese herbal medicines as raw materials, has better curative effect, reasonable compatibility, synergistic effect, clear effect, safety and no toxic or side effect, has wide application prospect and market space.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition of a lucid ganoderma nerve-soothing capsule, a preparation method thereof and a preparation method of the traditional Chinese medicine composition.
The lucid ganoderma nerve-soothing capsule has the following effects: has effects of nourishing blood and tranquilizing mind. Can be used for treating insomnia, dreaminess, dizziness, asthenia, and neurasthenia.
The traditional Chinese medicine composition of the lucid ganoderma nerve-soothing capsule is characterized by being prepared from the following raw material medicines:
ganoderma lucidum, cortex Albizziae, caulis Polygoni Multiflori, fructus Schisandrae chinensis, fructus Ligustri Lucidi, fructus Jujubae, semen Ziziphi Spinosae, and radix Glycyrrhizae.
The traditional Chinese medicine composition of the lucid ganoderma nerve-soothing capsule is characterized by being prepared from the following raw material medicines in parts by weight:
the traditional Chinese medicine composition of the lucid ganoderma nerve-soothing capsule is characterized by being prepared from the following raw medicines in a preferred weight ratio:
the preparation method of the traditional Chinese medicine composition of the lucid ganoderma nerve-soothing capsule comprises the following steps:
pulverizing Ganoderma into coarse powder; reflux-extracting caulis Polygoni Multiflori and fructus Schisandrae chinensis with 70% ethanol twice (each for 2 hr, 6 times and 4 times respectively), mixing extractive solutions, filtering, recovering ethanol, and concentrating to obtain fluid extract with relative density of 1.25-1.30 at 60 deg.C; decocting the rest five materials of cortex Albizziae, fructus Ligustri Lucidi, fructus Jujubae, semen Ziziphi Spinosae and Glycyrrhrizae radix with 8 times of water for 2 hr, and 6 times of water for 1.5 hr, mixing decoctions, filtering, and concentrating the filtrate to obtain fluid extract with relative density of 1.25-1.30 at 60 deg.C; mixing with the above fluid extract, adding Ganoderma coarse powder, mixing, drying at 70 deg.C under reduced pressure, pulverizing into fine powder, granulating with 85% ethanol, drying at 70 deg.C, grading, and making into capsule 1000 granules.
The invention has the advantages that: the Chinese herbal medicines are used as raw materials, so that the traditional Chinese medicine composition has the advantages of better curative effect, reasonable compatibility, synergistic effect, clear effect, safety and no toxic or side effect. Has obvious curative effect on insomnia, dreaminess, dizziness, hypodynamia and neurasthenia caused by heart-blood deficiency.
The invention has the beneficial effects that:
insomnia refers to a lack of sleep due to various causes. Typically including insufficient sleep time, depth, and recovery. There may be forms of difficulty falling asleep, frequent waking up, and early waking up. According to the traditional Chinese medicine, insomnia can be diagnosed by people who have the main clinical manifestations of insufficient sleep time, difficulty in falling asleep, or easy waking after sleeping. The main symptoms of insomnia are sleep deficiency, and are often accompanied by a plurality of uncomfortable symptoms and mental manifestations, such as dizziness, palpitation, shortness of breath, tiredness, hypodynamia, poor appetite, spontaneous perspiration, night sweat, tinnitus, deafness, extreme vigilance, timidity, fear, irritability, fullness in chest and hypochondrium, nausea, bitter taste, soreness of waist and legs, inattention, amnesia, decreased work and learning efficiency, and even loss of work and learning ability. Severe insomnia can also induce psychosomatic disorders such as wasting, tachycardia, diarrhea, constipation, elevated blood pressure, peptic ulcer disease, depression, anxiety, and even suicidal behavior. The traditional Chinese medicine considers that insomnia is mainly caused by internal factors. Such as physical weakness, anxiety, depression, etc., and also diet-related. Insomnia involves many zang-fu organs, such as heart, liver, spleen, kidney, etc., and the main pathological changes in heart are directly related to whether the heart spirit is calm or calm. If the heart stores spirit and the heart is calm, it will sleep normally, but not sleep if the heart is restless. Either heart meridian disorder or spleen disease, kidney disease, liver disease and stomach disease affecting the heart can cause insomnia. If the heart is damaged, heart-blood deficiency, malnutrition of heart-mind and restlessness will occur, so it will not become sleep. The insomnia caused by heart-blood deficiency can also be seen in weak people, or postpartum blood loss, pregnant women with excessive fertility, the elderly with body weakness, and the like, and the key point is heart-blood deficiency. Traditional Chinese medicine considers that sleep is mainly based on heart spirit and is a natural and regular transformation result of yin and yang qi, and once the rule is broken, insomnia can be caused.
The invention gives full play to the resource advantages of traditional Chinese medicine, applies the theoretical guidance and clinical practice of traditional Chinese medicine, aims at various reasons causing insomnia and neurasthenia, and is prepared by taking ganoderma lucidum, cortex albiziae, caulis polygoni multiflori, schisandra chinensis, glossy privet fruit, Chinese date, spina date seed and liquorice as raw material medicines and processing the raw material medicines by a modern process. In the formula, cortex albiziae is sweet and neutral in nature, enters heart, liver and lung channels, and nourishes heart and soothes nerves, and is used as a monarch drug in the formula. Ganoderma lucidum is sweet and neutral, and has the effects of nourishing heart-qi, calming essence, tonifying liver and benefiting qi; the vine of multiflower knotweed is sweet and neutral in nature, enters heart and liver channels, and can nourish blood, tranquilize mind and benefit liver; the spina date seed is sweet, sour and mild, and has liver, gallbladder and heart channels, and can nourish heart, tonify liver, calm heart and tranquilize mind, and the three medicines are used together as ministerial medicines; the schisandra chinensis is sour, sweet and warm in nature, enters lung, heart and kidney channels, and tonifies the kidney and calms the heart; the glossy privet fruit is sweet, bitter and cool in nature, enters liver and kidney channels, and nourishes liver and kidney; the Chinese dates are sweet and warm in nature, enter spleen, stomach and heart channels, can warm and tonify spleen qi, nourish blood and tranquilize mind, and are used as adjuvant drugs; licorice root, radix Glycyrrhizae is sweet and neutral in nature, and enters heart, lung, spleen and stomach meridians, and is used as a guiding drug to harmonize the property of the drug, strengthen the spleen and harmonize the middle energizer. The medicines are combined to play the effects of nourishing blood, soothing nerves, clearing away heart-fire and relieving restlessness. The traditional Chinese medicine composition has the advantages of compact pathogenesis, reasonable formula and obvious curative effect, related researches prove the effectiveness and safety of the traditional Chinese medicine composition, modern pharmacological experimental researches prove that the traditional Chinese medicine composition is natural, safe, small in side effect and the like, has the advantages that chemical medicines can not replace the traditional Chinese medicine composition, fully shows good application prospect and has wide market prospect.
By searching Chinese patent and literature databases, patents and research literatures which are the same as or similar to the formula of the Chinese patent and literature databases are not found, the formula of the invention has innovative design theory and thought, and the Chinese patent medicine for treating insomnia, dreaminess, dizziness and hypodynamia caused by heart-blood deficiency and neurasthenia with the symptoms is developed on the basis of the formula of the invention, so that the market demand prospect is wide.
The main pharmacodynamic tests are as follows
Compared with the prior art, the ganoderma lucidum nerve-soothing capsule of the invention has the experimental purposes that: through pharmacological experimental study on the effects of the ganoderma lucidum tranquilizing capsules of the invention on nourishing blood, tranquillizing and the like and the prior arts CN101700270A and CN103550629A, the pharmacological effects of the ganoderma lucidum tranquilizing capsules of the invention are observed by comparing with the prior arts CN101700270A and CN 103550629A.
Drugs for testing:
1. a group: for the prior art, the preparation method is prepared according to the method of example 2 in the specific implementation mode of Chinese patent publication No. CN101700270A, namely 'a traditional Chinese medicine composition for neurasthenia and a preparation method and a quality control method thereof', which is published in 5-2010.
b group: for the prior art, the traditional Chinese medicine composition is prepared according to the method of example 1 in the specific implementation mode of a Chinese patent publication with the publication number of CN103550629A, namely, "ganoderma lucidum nerve-soothing composition, liniment, a preparation method and application thereof" in 2-5-2-2014.
2. The invention relates to a ganoderma lucidum nerve-soothing capsule: prepared according to the formula and the preparation method of the embodiment 1 of the specification.
Purpose of the experiment: through pharmacological experimental researches on the ganoderma lucidum nerve-soothing capsule group, the group a and the group b for tranquilizing, hypnotizing, resisting depression and fatigue, improving the immunity of the organism and the like, the ganoderma lucidum nerve-soothing capsule group is compared with the group a and the group b, and the strength of the pharmacological action is observed.
The test method comprises the following steps: the influence of the ganoderma lucidum nerve-soothing capsule group, the group a and the group b on the spontaneous activity of a mouse; effect on sleep time in mice; effects on antidepressant action in mice; effects on anti-fatigue effects in mice; influence on hypoxia tolerance of mice.
First, influence on spontaneous Activity of mice
Experimental Material
1. Animals: the Kunming mouse has both male and female bodies and has the weight of 18-22 g.
2. Medicine preparation: the lucid ganoderma nerve-soothing capsule disclosed by the invention is prepared from three dosage groups, namely a large dosage group, a medium dosage group and a small dosage group; group a and group b. The medicine is prepared by distilled water before experiment and administered by intragastric administration.
Experimental methods
60 Kunming mice, half of male and female, with the weight of 18-22 g, were randomly divided into 6 groups of 10 mice each. The control group was perfused with the same volume of normal saline; the large, medium and small dose groups of the lucid ganoderma nerve-soothing capsule are respectively administrated with 4.8, 2.4 and 1.2g crude drugs/kg by intragastric administration; the gavage administration of group a and group b was 2.4g crude drug/kg. Each group was administered orally at 2.0mL/100g weight for 15d, 1/d, mice were placed in an activity box for 5min before the last administration, and 15min after the last administration, mice were placed in an activity measurement box, 4 mice were measured simultaneously each time, one in each activity box, and the time for 2min of the mice to ambulate was recorded. The experimental results are as follows: see table 1.
TABLE 1 Effect on spontaneous mouse Activity
P < 0.05, P < 0.01 compared to control; the ratio of delta P to a group a is less than 0.05; the ratio # P to group b was < 0.05.
The results show that: the ganoderma lucidum nerve-soothing capsule group, the group a and the group b can obviously reduce the spontaneous activity ambulation time of mice, the group a and the group b have statistical difference (P is less than 0.05) compared with a control group, and the large, medium and small dose groups of the ganoderma lucidum nerve-soothing capsule have very significant difference (P is less than 0.01) compared with the control group; compared with the group a and the group b, the large-dose group of the ganoderma lucidum nerve-soothing capsule has statistical difference (P is less than 0.05). Therefore, the tranquilizing and nerve-soothing ganoderma lucidum capsule group has stronger tranquilizing and nerve-soothing effects than the group a and the group b.
Second, influence on sleep time of mice
Experimental Material
1. Animals: the Kunming mouse has both male and female bodies and has the weight of 18-22 g.
2. Medicine preparation: the lucid ganoderma nerve-soothing capsule disclosed by the invention is prepared from three dosage groups, namely a large dosage group, a medium dosage group and a small dosage group; group a and group b. The medicine is prepared by distilled water before experiment and administered by intragastric administration.
Experimental methods
60 Kunming mice, half of male and female, with the weight of 18-22 g, were randomly divided into 6 groups of 10 mice each. The control group was perfused with the same volume of normal saline; the large, medium and small dose groups of the lucid ganoderma nerve-soothing capsule are respectively administrated with 4.8, 2.4 and 1.2g crude drugs/kg by intragastric administration; the gavage administration of group a and group b was 2.4g crude drug/kg. Each group was orally administered at 2.0mL/100g body weight for 15d, 1 time/d, and intraperitoneally injected at 10mL/kg with pentobarbital sodium 50mg/kg 15min after the last administration, and the time from disappearance of the righting reflex to awakening of the mice was recorded. The experimental results are as follows: see Table 2
TABLE 2 Effect on sleep time in mice
P < 0.05, P < 0.01 compared to control; the ratio of delta P to a group a is less than 0.05; the ratio # P to group b was < 0.05.
The results show that the ganoderma lucidum nerve-soothing capsule group, the group a and the group b can obviously prolong the sleep time of the pentobarbital sodium induced mice, the group a and the group b have statistical difference (P is less than 0.05) compared with a control group, and the large, medium and small dose groups of the ganoderma lucidum nerve-soothing capsule have very significant difference (P is less than 0.01) compared with the control group; compared with the group a and the group b, the large-dose group of the ganoderma lucidum nerve-soothing capsule has statistical difference (P is less than 0.05). Therefore, the ganoderma lucidum nerve-soothing capsule group has stronger hypnotic effect than the group a and the group b.
Influence on antidepressant action in mice
Experimental Material
1. Animals: the Kunming mouse has both male and female bodies and has the weight of 18-22 g.
2. Medicine preparation: the lucid ganoderma nerve-soothing capsule disclosed by the invention is prepared from three dosage groups, namely a large dosage group, a medium dosage group and a small dosage group; group a and group b. The medicine is prepared by distilled water before experiment and administered by intragastric administration.
Experimental methods
60 Kunming mice, half of male and female, with the weight of 18-22 g, were randomly divided into 6 groups of 10 mice each. The control group was perfused with the same volume of normal saline; the large, medium and small dose groups of the lucid ganoderma nerve-soothing capsule are respectively administrated with 4.8, 2.4 and 1.2g crude drugs/kg by intragastric administration; the gavage administration of group a and group b was 2.4g crude drug/kg. Each group was orally administered at 2.0mL/100g body weight for 15d, 1 time/d, 15min after the last administration, the tail 2cm of each group was fixed on a horizontal stick, the mouse was suspended with the head about 5cm from the table, the animal was kept in sight on both sides of the suspension by plates, and the time during which each group suspended the tail within 4min was observed and recorded.
The experimental results are as follows: see Table 3
TABLE 3 Effect on antidepressant action in mice
P < 0.05, P < 0.01 compared to control; the ratio of delta P to a group a is less than 0.05; the ratio # P to group b was < 0.05.
The results show that the ganoderma lucidum nerve-soothing capsule group, the group a and the group b obviously reduce the tail suspension immobility time, the group a and the group b have statistical difference (P is less than 0.05) compared with a control group, and the large, medium and small dose groups of the ganoderma lucidum nerve-soothing capsule have very significant difference (P is less than 0.01) compared with the control group; compared with the group a and the group b, the large-dose group of the ganoderma lucidum nerve-soothing capsule has statistical difference (P is less than 0.05). Therefore, the ganoderma lucidum nerve-soothing capsule group has stronger antidepressant effect than the group a and the group b.
Fourth, the effect on the anti-fatigue action of mice
Experimental Material
1. Animals: the Kunming mouse has both male and female bodies and has the weight of 18-22 g.
2. Medicine preparation: the lucid ganoderma nerve-soothing capsule disclosed by the invention is prepared from three dosage groups, namely a large dosage group, a medium dosage group and a small dosage group; group a and group b. The medicine is prepared by distilled water before experiment and administered by intragastric administration.
Experimental methods
60 Kunming mice, half of male and female, with the weight of 18-22 g, were randomly divided into 6 groups of 10 mice each. The control group was perfused with the same volume of normal saline; the large, medium and small dose groups of the lucid ganoderma nerve-soothing capsule are respectively administrated with 4.8, 2.4 and 1.2g crude drugs/kg by intragastric administration; the gavage administration of group a and group b was 2.4g crude drug/kg. Each group was orally administered at 2.0mL/100g body weight for 15d, 1 time/d. 60min after the last administration, 1.5g of hydrophobic clay (about 5% of the weight of the mouse) was attached to the back of the mouse, and the mice were placed in a large water tank and tested. The water temperature and the environment temperature are controlled to be about 30 ℃ and the water depth is 30 cm. The water surface is continuously stirred to stimulate the mouse to swim continuously, the swimming time from water entry to exhaustion of the mouse is recorded by a stopwatch, the swimming action of the mouse is observed to be obviously disordered and can not be maintained any more, and the swimming motion of the mouse is judged to be exhausted when the head of the mouse enters the water for 5s and does not float. The time from the start of swimming to exhaustion of the mouse was recorded. The experimental results are as follows: see Table 4
TABLE 4 Effect on anti-fatigue Effect of mice
P < 0.05, P < 0.01 compared to control; the ratio of delta P to a group a is less than 0.05; the ratio # P to group b was < 0.05.
The results show that: the ganoderma lucidum nerve-soothing capsule group, the group a and the group b can obviously prolong the weight-bearing swimming time of mice, the group a and the group b have statistical difference (P is less than 0.05) compared with a control group, and the fatigue resistance of the mice enhanced by the ganoderma lucidum nerve-soothing capsule group is not as good as that of each group of the ganoderma lucidum nerve-soothing capsule; compared with a control group, the large, medium and small dosage groups of the lucid ganoderma nerve-soothing capsule have very significant difference (P is less than 0.01); compared with the group a and the group b, the large-dose group of the ganoderma lucidum nerve-soothing capsule has statistical difference (P is less than 0.05). Therefore, the ganoderma lucidum nerve-soothing capsule group has stronger anti-fatigue effect than the group a and the group b.
Fifth, influence on hypoxia tolerance of mice
Experimental Material
1. Animals: the Kunming mouse has both male and female bodies and has the weight of 18-22 g.
2. Medicine preparation: the lucid ganoderma nerve-soothing capsule disclosed by the invention is prepared from three dosage groups, namely a large dosage group, a medium dosage group and a small dosage group; group a and group b. The medicine is prepared by distilled water before experiment and administered by intragastric administration.
Experimental methods
60 Kunming mice, half of male and female, with the weight of 18-22 g, were randomly divided into 6 groups of 10 mice each. The control group was perfused with the same volume of normal saline; the large, medium and small dose groups of the lucid ganoderma nerve-soothing capsule are respectively administrated with 4.8, 2.4 and 1.2g crude drugs/kg by intragastric administration; the gavage administration of group a and group b was 2.4g crude drug/kg. Each group is orally administered for 15d, 1 time/d according to 2.0mL/100g body weight, 15min after the last administration, and the mice are placed into a wide-mouth bottle containing 15g of soda lime for hypoxia tolerance experiment. Coating vaseline on the wide-mouth bottle mouth, placing one mouse in each bottle, covering and sealing, and immediately starting timing. The time of death of the mice due to hypoxia was recorded using the cessation of breathing as an indicator. The experimental results are as follows: see Table 5
TABLE 5 Effect on hypoxia tolerance in mice
P < 0.05, P < 0.01 compared to control; the ratio of delta P to a group a is less than 0.05; the ratio # P to group b was < 0.05.
The results show that: the ganoderma lucidum nerve-soothing capsule group, the group a and the group b can prolong the survival time of a mouse in an anoxic environment, the group a and the group b have statistical difference (P is less than 0.05) compared with a control group, and the large, medium and small dose groups have very significant difference (P is less than 0.01) compared with the control group; compared with the group a and the group b, the large-dose group of the ganoderma lucidum nerve-soothing capsule has stronger hypoxia-resistant effect and has statistical difference (P is less than 0.05). Therefore, the ganoderma lucidum nerve-soothing capsule group has stronger organism immunity improving effect than the group a and the group b.
The experimental results are as follows: the ganoderma lucidum nerve-soothing capsule group, the group a and the group b can obviously reduce the spontaneous activity times of mice; the sleep time of the mouse can be obviously prolonged; obviously reducing the immobility time of the tail suspension of the mouse; the weight-bearing swimming time of the mouse can be obviously prolonged; can prolong the survival time of the mouse in an anoxic environment.
And (4) conclusion: the ganoderma lucidum nerve-soothing capsule group, the group a and the group b have strong pharmacological effects of tranquilizing and allaying excitement, hypnosis, depression resistance, fatigue resistance, organism immunity improvement and the like, so that the ganoderma lucidum nerve-soothing capsule group has better clinical curative effect on neurasthenia than the group a and the group b.
The specific implementation mode of the invention is as follows:
the invention is further illustrated, but is not intended to be limited, by the following specific examples.
Example 1:
the invention is prepared from the following raw material medicines in parts by weight:
the preparation method comprises the following steps:
pulverizing Ganoderma into coarse powder; reflux-extracting caulis Polygoni Multiflori and fructus Schisandrae chinensis with 70% ethanol twice (each for 2 hr, 6 times and 4 times respectively), mixing extractive solutions, filtering, recovering ethanol, and concentrating to obtain fluid extract with relative density of 1.25-1.30 at 60 deg.C; decocting the rest five materials of cortex Albizziae, fructus Ligustri Lucidi, fructus Jujubae, semen Ziziphi Spinosae and Glycyrrhrizae radix with 8 times of water for 2 hr, and 6 times of water for 1.5 hr, mixing decoctions, filtering, and concentrating the filtrate to obtain fluid extract with relative density of 1.25-1.30 at 60 deg.C; mixing with the above fluid extract, adding Ganoderma coarse powder, mixing, drying at 70 deg.C under reduced pressure, pulverizing into fine powder, granulating with 85% ethanol, drying at 70 deg.C, grading, and making into capsule 1000 granules.
Example 2:
the invention is prepared from the following raw material medicines in parts by weight:
the preparation method comprises the following steps:
pulverizing Ganoderma into coarse powder; reflux-extracting caulis Polygoni Multiflori and fructus Schisandrae chinensis with 70% ethanol twice (each for 2 hr, 6 times and 4 times respectively), mixing extractive solutions, filtering, recovering ethanol, and concentrating to obtain fluid extract with relative density of 1.25-1.30 at 60 deg.C; decocting the rest five materials of cortex Albizziae, fructus Ligustri Lucidi, fructus Jujubae, semen Ziziphi Spinosae and Glycyrrhrizae radix with 8 times of water for 2 hr, and 6 times of water for 1.5 hr, mixing decoctions, filtering, and concentrating the filtrate to obtain fluid extract with relative density of 1.25-1.30 at 60 deg.C; mixing with the above fluid extract, adding Ganoderma coarse powder, mixing, drying at 70 deg.C under reduced pressure, pulverizing into fine powder, granulating with 85% ethanol, drying at 70 deg.C, grading, and making into capsule 1000 granules.
Example 3:
the invention is prepared from the following raw material medicines in parts by weight:
the preparation method comprises the following steps:
pulverizing Ganoderma into coarse powder; reflux-extracting caulis Polygoni Multiflori and fructus Schisandrae chinensis with 70% ethanol twice (each for 2 hr, 6 times and 4 times respectively), mixing extractive solutions, filtering, recovering ethanol, and concentrating to obtain fluid extract with relative density of 1.25-1.30 at 60 deg.C; decocting the rest five materials of cortex Albizziae, fructus Ligustri Lucidi, fructus Jujubae, semen Ziziphi Spinosae and Glycyrrhrizae radix with 8 times of water for 2 hr, and 6 times of water for 1.5 hr, mixing decoctions, filtering, and concentrating the filtrate to obtain fluid extract with relative density of 1.25-1.30 at 60 deg.C; mixing with the above fluid extract, adding Ganoderma coarse powder, mixing, drying at 70 deg.C under reduced pressure, pulverizing into fine powder, granulating with 85% ethanol, drying at 70 deg.C, grading, and making into capsule 1000 granules.
Example 4:
the invention is prepared from the following raw material medicines in parts by weight:
the preparation method comprises the following steps:
pulverizing Ganoderma into coarse powder; reflux-extracting caulis Polygoni Multiflori and fructus Schisandrae chinensis with 70% ethanol twice (each for 2 hr, 6 times and 4 times respectively), mixing extractive solutions, filtering, recovering ethanol, and concentrating to obtain fluid extract with relative density of 1.25-1.30 at 60 deg.C; decocting the rest five materials of cortex Albizziae, fructus Ligustri Lucidi, fructus Jujubae, semen Ziziphi Spinosae and Glycyrrhrizae radix with 8 times of water for 2 hr, and 6 times of water for 1.5 hr, mixing decoctions, filtering, and concentrating the filtrate to obtain fluid extract with relative density of 1.25-1.30 at 60 deg.C; mixing with the above fluid extract, adding Ganoderma coarse powder, mixing, drying at 70 deg.C under reduced pressure, pulverizing into fine powder, granulating with 85% ethanol, drying at 70 deg.C, grading, and making into capsule 1000 granules.
Example 5:
the invention is prepared from the following raw material medicines in parts by weight:
the preparation method comprises the following steps:
pulverizing Ganoderma into coarse powder; reflux-extracting caulis Polygoni Multiflori and fructus Schisandrae chinensis with 70% ethanol twice (each for 2 hr, 6 times and 4 times respectively), mixing extractive solutions, filtering, recovering ethanol, and concentrating to obtain fluid extract with relative density of 1.25-1.30 at 60 deg.C; decocting the rest five materials of cortex Albizziae, fructus Ligustri Lucidi, fructus Jujubae, semen Ziziphi Spinosae and Glycyrrhrizae radix with 8 times of water for 2 hr, and 6 times of water for 1.5 hr, mixing decoctions, filtering, and concentrating the filtrate to obtain fluid extract with relative density of 1.25-1.30 at 60 deg.C; mixing with the above fluid extract, adding Ganoderma coarse powder, mixing, drying at 70 deg.C under reduced pressure, pulverizing into fine powder, granulating with 85% ethanol, drying at 70 deg.C, grading, and making into capsule 1000 granules.
Example 6:
the invention is prepared from the following raw material medicines in parts by weight:
the preparation method comprises the following steps:
pulverizing Ganoderma into coarse powder; reflux-extracting caulis Polygoni Multiflori and fructus Schisandrae chinensis with 70% ethanol twice (each for 2 hr, 6 times and 4 times respectively), mixing extractive solutions, filtering, recovering ethanol, and concentrating to obtain fluid extract with relative density of 1.25-1.30 at 60 deg.C; decocting the rest five materials of cortex Albizziae, fructus Ligustri Lucidi, fructus Jujubae, semen Ziziphi Spinosae and Glycyrrhrizae radix with 8 times of water for 2 hr, and 6 times of water for 1.5 hr, mixing decoctions, filtering, and concentrating the filtrate to obtain fluid extract with relative density of 1.25-1.30 at 60 deg.C; mixing with the above fluid extract, adding Ganoderma coarse powder, mixing, drying at 70 deg.C under reduced pressure, pulverizing into fine powder, granulating with 85% ethanol, drying at 70 deg.C, grading, and making into capsule 1000 granules.
Claims (4)
1. The traditional Chinese medicine composition of the lucid ganoderma nerve-soothing capsule is characterized by being prepared from the following raw medicines in parts by weight:
2. the traditional Chinese medicine composition of ganoderma lucidum nerve calming capsule according to claim 1, which is characterized by being prepared from the following raw material medicines in a preferable weight ratio:
3. the preparation method of the traditional Chinese medicine composition of the ganoderma lucidum nerve-soothing capsule according to claim 1 or 2, which is characterized by comprising the following steps of: pulverizing Ganoderma into coarse powder; reflux-extracting caulis Polygoni Multiflori and fructus Schisandrae chinensis with 70% ethanol twice (each for 2 hr, 6 times and 4 times respectively), mixing extractive solutions, filtering, recovering ethanol, and concentrating to obtain fluid extract with relative density of 1.25-1.30 at 60 deg.C; decocting the rest five materials of cortex Albizziae, fructus Ligustri Lucidi, fructus Jujubae, semen Ziziphi Spinosae and Glycyrrhrizae radix with 8 times of water for 2 hr, and 6 times of water for 1.5 hr, mixing decoctions, filtering, and concentrating the filtrate to obtain fluid extract with relative density of 1.25-1.30 at 60 deg.C; mixing with the above fluid extract, adding Ganoderma coarse powder, mixing, drying at 70 deg.C under reduced pressure, pulverizing into fine powder, granulating with 85% ethanol, drying at 70 deg.C, grading, and making into capsule 1000 granules.
4. The traditional Chinese medicine composition of ganoderma lucidum tranquilizing capsule according to claim 1 or 2, which is mainly used for treating insomnia, dreaminess, dizziness and hypodynamia caused by heart-blood deficiency, and patients with neurasthenia with the above symptoms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111271142.8A CN113842411A (en) | 2021-10-29 | 2021-10-29 | Traditional Chinese medicine composition of lucid ganoderma nerve-soothing capsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111271142.8A CN113842411A (en) | 2021-10-29 | 2021-10-29 | Traditional Chinese medicine composition of lucid ganoderma nerve-soothing capsule and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113842411A true CN113842411A (en) | 2021-12-28 |
Family
ID=78983487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111271142.8A Pending CN113842411A (en) | 2021-10-29 | 2021-10-29 | Traditional Chinese medicine composition of lucid ganoderma nerve-soothing capsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113842411A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114558041A (en) * | 2022-02-22 | 2022-05-31 | 广西伟健药业有限公司 | Preparation method of Lingling capsule |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450122A (en) * | 2008-12-30 | 2009-06-10 | 南京中医药大学 | Traditional Chinese medicine preparation for treating insomnia and preparation method and use thereof |
-
2021
- 2021-10-29 CN CN202111271142.8A patent/CN113842411A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450122A (en) * | 2008-12-30 | 2009-06-10 | 南京中医药大学 | Traditional Chinese medicine preparation for treating insomnia and preparation method and use thereof |
Non-Patent Citations (4)
| Title |
|---|
| 丁青龙等: "夜宁胶囊治疗神经衰弱临床观察", 《中国现代药物应用》 * |
| 杨士友等: "夜宁糖浆和口服液的药效学研究", 《中药药理与临床》 * |
| 王争平等: "夜宁胶囊治疗神经衰弱及神经衰弱症候群的临床研究", 《中国现代药物应用》 * |
| 许利平: "《实用中成药手册》", 31 October 2010 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114558041A (en) * | 2022-02-22 | 2022-05-31 | 广西伟健药业有限公司 | Preparation method of Lingling capsule |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107126485B (en) | Traditional Chinese medicine composition for assisting in improving sleep and preparation method and application thereof | |
| CN102764340B (en) | Traditional Chinese medicine composite capable of improving sleep and preparation method and application thereof | |
| CN102283999B (en) | Traditional Chinese medicine preparation for treating insomnia | |
| CN101032560B (en) | Chinese medicine composition for treating somnipathy and preparing method thereof | |
| CN102526474B (en) | Chinese medicine composition for treating neurasthenia | |
| CN103251867A (en) | Chinese herbal compound medicine for treating diabetes mellitus and preparation method thereof | |
| CN102198241B (en) | Medicine for alleviating nervousness and taking care of sub-health | |
| CN1121811A (en) | Drug prescription for treatment of neurosis and preparing method thereof | |
| CN106214964A (en) | Traditional Chinese medicine for soothing nerves preparation | |
| CN106581460A (en) | Intractable insomnia treatment medicine | |
| CN111840394B (en) | Pharmaceutical composition for insomnia and preparation method thereof | |
| CN113842411A (en) | Traditional Chinese medicine composition of lucid ganoderma nerve-soothing capsule and preparation method thereof | |
| CN101700336B (en) | Chinese herba preparation for curing craniocerebra trauma residual headache and preparation method | |
| CN108355088A (en) | A kind of spina date seed medicinal liquor and preparation method thereof improving sleep quality | |
| CN101732566B (en) | Traditional Chinese medicine compound preparation for tonifying liver and kidney and strengthening bones and muscles | |
| CN115252753B (en) | Traditional Chinese medicine composition for treating insomnia and application thereof | |
| CN105456818A (en) | Traditional Chinese medicine composition containing folium artemisiae argyi and being capable of treating insomnia and preparation method of traditional Chinese medicine composition | |
| CN112316051B (en) | Traditional Chinese medicine composition for nourishing blood and reducing phlegm as well as traditional Chinese medicine preparation, preparation method and application thereof | |
| CN104225295A (en) | Composition for improving sleep, and preparation method and application thereof | |
| CN111298020B (en) | Traditional Chinese medicine composition with anti-fatigue effect and preparation method and application thereof | |
| CN100360152C (en) | Medicinal composition for treating insomnia and its preparing process | |
| CN112843174A (en) | Traditional Chinese medicine composition with functions of tonifying spleen, nourishing heart and soothing nerves, preparation method and application | |
| CN103028034A (en) | Pharmaceutical composition for treating insomnia and preparation method | |
| CN103071080B (en) | Traditional Chinese medicine preparation for treating depressive disorder | |
| CN105362831A (en) | Traditional Chinese medicine preparation for treating insomnia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211228 |
|
| WD01 | Invention patent application deemed withdrawn after publication |